Transition to KPL-387 Monotherapy Dosing & Administration Study

ClinicalTrials.gov ID: NCT07288216

Public ClinicalTrials.gov record NCT07288216. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 22, 2026, 9:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Posology Study With Long-Term Extension in Participants With Well-Controlled Recurrent Pericarditis to Evaluate the Efficacy and Safety of Transition Regimens to KPL-387 Monotherapy From Standard Therapies

Study identification

NCT ID: NCT07288216
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Kiniksa Pharmaceuticals International, plc; Industry
Enrollment: 80 participants

Conditions and interventions

Conditions

Interventions

KPL-387 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 80 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 24, 2026
Primary completion: Dec 30, 2027
Completion: Dec 30, 2029
Last update posted: Jul 8, 2026

2026 – 2029

United States locations

U.S. sites: 15
U.S. states: 10
U.S. cities: 14

Facility	City	State	ZIP	Site status
Investigational Site 031	Phoenix	Arizona	85054	Recruiting
Investigational Site 014	Los Angeles	California	90048	Recruiting
Investigational Site 002	Santa Monica	California	90404	Recruiting
Investigational Site 039	Jacksonville	Florida	32224	Recruiting
Investigational Site 013	Chicago	Illinois	60611	Recruiting
Investigational Site 025	Baltimore	Maryland	21287	Recruiting
Investigational Site 028	Rochester	Minnesota	55905	Recruiting
Investigational Site 011	New York	New York	10016	Recruiting
Investigational Site 003	New York	New York	10032	Recruiting
Investigational Site 009	Cincinnati	Ohio	45219	Recruiting
Investigational Site 005	Austin	Texas	78705	Recruiting
Investigational Site 006	Houston	Texas	77030	Recruiting
Investigational Site 004	Charlottesville	Virginia	22903	Recruiting
Investigational Site 001	Norfolk	Virginia	23507	Recruiting
Investigational Site 008	Richmond	Virginia	23284	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07288216, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 8, 2026 · Synced Jul 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07288216 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →